Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Maintains Positive Outlook on Endava with Adjusted Price Target

Elaine Mendonca by Elaine Mendonca
March 1, 2024
in Breaking News
0
Biotechnology Stock Bull Market
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

TD Cowen analyst Bryan Bergin has reiterated his positive outlook on Endava (NYSE: DAVA), maintaining an Outperform rating. However, he has adjusted the price target to $52, down from $85. Despite this revision, the average one-year price target for Endava plc – ADR stands at $72.80, with projections ranging from $53.53 to $98.48.

Analysts surveyed by Capital IQ also give Endava an average outperform rating, with a price target range of $53 to $98.48. The company offers technology services and solutions across various industries including payments, financial services, technology, media, telecom, consumer products, retail, mobility, and healthcare.

Endava leverages its Distributed Enterprise Agile scaling framework to help clients develop digital solutions and maximize their business opportunities.

DAVA Stock Plummets 41.76% on March 1, 2024: Pre-Market Gains Offer Hope for Recovery

On March 1, 2024, DAVA stock experienced a significant drop in price, with shares decreasing by $26.65 since the market last closed. This represents a 41.76% drop in value, with the stock closing at $37.17. However, there seems to be some positive movement in pre-market trading, as the stock has risen by $0.72.

Investors and analysts will be closely monitoring DAVA’s performance in the coming days to see if the pre-market gains will hold and if the stock can start to recover from its recent losses. It will be important to watch for any news or developments that could impact the stock’s price movement.

DAVA Stock Analysis: Mixed Performances on March 1, 2024

On March 1, 2024, DAVA stock experienced mixed performances based on the financial data provided by CNN Money. The total revenue for the company stood at $955.89 million for the past year, showing a 9.84% increase compared to the previous year. However, the total revenue for the second quarter was $227.72 million, reflecting a 4.5% decrease compared to the previous quarter.

Similarly, the net income for DAVA was reported at $113.26 million for the past year, holding flat compared to the previous year. However, the net income for the second quarter was $10.36 million, indicating a significant 33.83% decrease compared to the previous quarter.

Furthermore, the earnings per share (EPS) for DAVA stock was $1.95 for the past year, remaining flat compared to the previous year. However, the EPS for the second quarter was $0.18, showing a substantial 34.3% decrease compared to the previous quarter.

Overall, the financial performance of DAVA stock on March 1, 2024, was a mix of positive and negative indicators. Investors and analysts will closely monitor these financial indicators to assess the overall health and performance of DAVA stock in the coming months. It is essential for investors to conduct thorough research and analysis before making any investment decisions based on the financial data provided.

Tags: DAVA
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Ai Sleeping

Sleep Quality's Impact on Physical and Financial Well-Being

DVY stock news

Truist Securities Analyst Reiterates Hold Recommendation on Best Buy Co

Finances (2)

Truist Securities Analyst Maintains Hold Rating on Integra Lifesciences with Revised Price Target

Recommended

Alphabet Stock

EU Launches Fresh Antitrust Probe Into Alphabet

4 months ago
CarParts.Com Stock

CarParts.com Faces Critical Week Amid Leadership Shakeup and Earnings Release

5 months ago
Peloton Stock

Peloton’s Stock Rollercoaster: Profitability Meets Product Recall

4 months ago
Kraft Heinz Stock

A Radical Breakup: Kraft Heinz Plans Corporate Split to Reverse Fortunes

6 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Lexaria Bioscience Targets Multi-Billion Dollar Market with Side-Effect Solution

Watsco’s Dividend Hike Contrasts with Operational Headwinds

Pinduoduo’s Upcoming Earnings: A Critical Test for the E-Commerce Giant

XPeng Achieves Profitability Milestone Amid Strategic Mexican Launch

Oracle’s Backlog Soars on Cloud and AI Contract Momentum

Regulatory Scrutiny Looms Over Alphabet’s Aggressive AI Expansion

Trending

Microsoft Stock
AI & Quantum Computing

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

by Jackson Burston
March 25, 2026
0

Microsoft continues to post robust revenue growth, but the cost of maintaining its competitive edge is becoming...

Hesai Group Stock

Hesai Group’s Milestone Profit Tempered by Cautious Guidance

March 25, 2026
Pagerduty Inc Stock

PagerDuty Charts a New Course with Autonomous AI Systems

March 25, 2026
Lexaria Bioscience Stock

Lexaria Bioscience Targets Multi-Billion Dollar Market with Side-Effect Solution

March 25, 2026
Watsco Stock

Watsco’s Dividend Hike Contrasts with Operational Headwinds

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink
  • Hesai Group’s Milestone Profit Tempered by Cautious Guidance
  • PagerDuty Charts a New Course with Autonomous AI Systems

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com